Use of sphingosine-1-phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases

Details for Australian Patent Application No. 2004298760 (hide)

Owner Novartis AG

Inventors Kaneider, Nicole; Wiedermann, Christian J.; Brinkmann, Volker

Agent Davies Collison Cave

Pub. Number AU-B-2004298760

PCT Pub. Number WO2005/058295

Priority 0329498.0 19.12.03 GB

Filing date 17 December 2004

Wipo publication date 30 June 2005

Acceptance publication date 21 May 2009

International Classifications

A61K 31/00 (2006.01)

A61K 31/133 (2006.01) - having hydroxy groups, e.g. sphingosine

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

22 June 2006 PCT application entered the National Phase

  PCT publication WO2005/058295 Priority application(s): WO2005/058295

21 May 2009 Application Accepted

  Published as AU-B-2004298760

17 September 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004298761-Combination of (a) N- {5-[4-(4-methyl-piperazino-methyl)-benz oylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyri midine-amine and (b) at least one hypusination inhibitor and the use thereof

2004298758-Microemulsion preconcentrate comprising a renin inhibitor